The global leader in USAN/INN naming, partnering on 76% of USAN and 78% of INN drug name approvals!

367
Healthcare Clients
3198
Total Healthcare Names
36
Metabolic Disorders Names
CLIENTNAMECATEGORY
TEVA PHARMACEUTICAL INDUSTRIESalbusomatropinMetabolic Disorders
NGM BIOPHARMACEUTICALSaldaferminMetabolic Disorders
Ferring PHARMACEUTICALSapraglutideMetabolic Disorders
GileadcilofexorMetabolic Disorders
VALERION THERAPEUTICSclervonafusp alfaMetabolic Disorders
SANGAMO THERAPEUTICSdevafidugene civaparvovecMetabolic Disorders
CATABASIS PHARMACEUTICALSedasalonexentMetabolic Disorders
Genexineeftansomatropin alfaMetabolic Disorders
GileadfirsocostatMetabolic Disorders
BASF AGRICULTUREicosabutateMetabolic Disorders
GlaxoSmithKlinelinerixibatMetabolic Disorders
MillendolivoletideMetabolic Disorders
ASCENDIS PHARMAlonapegsomatropinMetabolic Disorders
SHIRE PHARMACEUTICALSmaralixibat chlorideMetabolic Disorders
CORCEPT THERAPEUTICSmiricorilantMetabolic Disorders
AGIOSmitapivatMetabolic Disorders
CATABASIS PHARMACEUTICALSnicodicosapentMetabolic Disorders
ALBIREOodevixibatMetabolic Disorders
LYSOGENEolenasufligene relduparvovecMetabolic Disorders
BIOMARINpegvaliaseMetabolic Disorders
Abeonarebisufligene etisparvovecMetabolic Disorders
MADRIGALresmetiromMetabolic Disorders
BIOMARINreveglucosidase alfaMetabolic Disorders
NOVO NORDISKsomapacitanMetabolic Disorders
VERSARTISsomavaratanMetabolic Disorders
SANGAMO THERAPEUTICStefidsogene civaparvovecMetabolic Disorders
BIOMARINtralesinidase alfaMetabolic Disorders
ULTRAGENYX PHARMACEUTICALtriheptanoinMetabolic Disorders
SHIRE PHARMACEUTICALSvalanafusp alfaMetabolic Disorders
REMD BIOTHERAPEUTICSvolagidemabMetabolic Disorders
REMD BIOTHERAPEUTICSvolagidemabMetabolic Disorders